The significantly elevated ABCG2 expression in acquired gefitinib-resistant NSCLC cells has been shown previously both in vitro and in vivo (Usuda et al., 2007; Zhu et al., 2015), but the involvement of ABCC10 in the acquired resistance to EGFR-TKIs has not been reported so far. Here, ABCG2 is linked to non-small cell lung carcinoma.